-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DAC-002 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DAC-002 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DAC-002 in Triple-Negative Breast Cancer (TNBC) Drug Details: DAC-002 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DAC-002 in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DAC-002 in Small-Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DAC-002 in Small-Cell Lung Cancer Drug Details: DAC-002 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ecubectedin in Rhabdomyosarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ecubectedin in Rhabdomyosarcoma Drug Details: Ecubectedin (PM-14) is under development for the treatment of solid...
-
Product Insights
Ureter Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Ureter Cancer - Drugs In Development, 2023’, provides an overview of the Ureter Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ureter Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Urethral Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Urethral Cancer - Drugs In Development, 2023’, provides an overview of the Urethral Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Urethral Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sym-021 in Metastatic Biliary Tract Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sym-021 in Metastatic Biliary Tract Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sym-021 in Metastatic Biliary Tract Cancer Drug Details: Sym-021 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RLY-2608 in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RLY-2608 in Metastatic Breast Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RLY-2608 in Metastatic Breast Cancer Drug Details: RLY-2608 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HTL-0039732 in Sarcomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HTL-0039732 in Sarcomas report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HTL-0039732 in Sarcomas Drug Details: HTL-0039732 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nemvaleukin Alfa in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Nemvaleukin Alfa in Non-Small Cell Lung Cancer Drug Details: Nemvaleukin alfa (ALKS-4230) is under development...